Metabolic acidosis is a frequent and potentially serious medical condition that occurs when the body produces too much acid or when the kidneys are not able to effectively remove acid from the body. Non-anion gap metabolic acidosis (NAGMA) is a specific type of metabolic acidosis that occurs when there is an accumulation of organic acids, such as lactic acid, in the body. This type of acidosis is typically caused by a variety of medical conditions, such as kidney failure, certain medications, and certain genetic disorders. In this article, we will explore the causes and treatment options for NAGMA. We will discuss the various medical conditions that can cause NAGMA, the medications that can contribute to this condition, and the genetic disorders that can lead to NAGMA. We will also discuss the various treatments available for NAGMA, including lifestyle changes, medications, and other treatments.
Non-anion gap metabolic acidosis (NAGMA) is a type of metabolic acidosis that occurs when there is an accumulation of organic acids, such as lactic acid, in the body. This type of acidosis is typically caused by a variety of medical conditions, such as kidney failure, certain medications, and certain genetic disorders. NAGMA is a type of metabolic acidosis that is characterized by an abnormally high level of acid in the blood. The acidity of the blood is measured using the anion gap, which is the difference between the concentrations of the two main types of electrolytes in the blood: anions and cations. In NAGMA, the anion gap is normal, meaning that the levels of anions and cations are equal.
What Causes Non-Anion Gap Metabolic Acidosis?
NAGMA is typically caused by a variety of medical conditions, medications, and genetic disorders. The most common causes of NAGMA include:
Kidney Failure
Kidney failure is one of the most common causes of NAGMA. When the kidneys are not functioning properly, they are unable to filter out the acids that are produced in the body, leading to an accumulation of acid in the blood.
Medications
Certain medications, such as diuretics and antifungal medications, can also cause NAGMA. These medications can interfere with the body’s ability to filter out acids, leading to an accumulation of acid in the blood.
Genetic Disorders
Certain genetic disorders, such as inherited metabolic disorders, can also lead to NAGMA. These disorders can interfere with the body’s ability to process and eliminate acids, leading to an accumulation of acid in the blood.
The treatment of NAGMA depends on the underlying cause of the condition. In some cases, lifestyle changes may be enough to reduce the acid levels in the blood. In other cases, medications may be needed to reduce the acid levels in the blood. In some cases, other treatments, such as dialysis, may be necessary.
Non-anion gap metabolic acidosis (NAGMA) is a type of metabolic acidosis that occurs when there is an accumulation of organic acids, such as lactic acid, in the body. NAGMA is typically caused by a variety of medical conditions, medications, and genetic disorders. The treatment of NAGMA depends on the underlying cause of the condition, and may include lifestyle changes, medications, and other treatments.
1.
Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
2.
FDA approves Blenrep for relapsed or refractory multiple myeloma
3.
X-ray and radar technology combined to reduce cancer screening risks
4.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
5.
Researchers discuss HER2-low and HER2-zero in breast cancer
1.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
2.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
3.
The New Era of Oncology: Key Updates and Clinical Insights
4.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
5.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation